CDC Issues EUA for Pfizer Vaccine for Pediatric Population, Ages 5-11

This news article has been archived.

On November 2, the CDC issued emergency use authorization (EUA) for the use of the Pfizer COVID-19 vaccine for the pediatric population ages 5-11 years.

The EUA comes after the FDA's review of Pfizer's vaccine trial and EUA authorization . The vaccine trial consisted of 2,268 child participants and used Pfizer’s two-dose vaccine regimen. Of the total pediatric participants, 1,518 received the vaccine and 750 received the placebo (saline).

The pediatric vaccine trial included a follow-up at or near 2 months after the participant’s second dose (data cutoff was October 8, 2021). Phase 2 and 3 clinical trials are still ongoing, click here to learn more about the pediatric vaccine clinical trials.

The Western States Scientific Safety Review Workgroup also reviewed the data and endorsed the vaccine.

The Washington State DOH is updating Vaccine Locator and will add an option for “Pfizer-BioNTech Pediatric” vaccine in the coming days. If you have questions or need help scheduling an appointment, call the state’s COVID-19 hotline at 833-VAX-HELP. Language assistance is available.

Children ages 5-11 represent around 9% of all reported coronavirus cases in the country, according to data presented to the FDA advisory panel and recently released State data show COVID-19 infections among children and youth are slowing.

To learn how to submit reports of adverse events following vaccination to the Vaccine Adverse Event Reporting System (VAERS), a vaccine safety monitoring system managed by CDC and FDA, visit the VAERS website, call the VAERS toll-free information line at 1-800-822-7967, or send an email to

Share on Facebook Share on Twitter Share on Linkedin Email this link

COVID-19 information pages are no longer updated. 

See the CDC's COVID website for current information and trends. 

<span class="translation_missing" title="translation missing:">Load Comment Text</span>